Update on biomarkers in neuromyelitis optica

Esther Melamed¹, Michael Levy¹, Patrick J Waters¹, Douglas Kazutoshi Sato¹, Jeffrey L Bennett¹, Gareth R John¹, Douglas C Hooper¹, Albert Saiz¹, Amit Bar-Or¹, Ho Jin Kim¹, Lakha Pandit¹, Maria Isabel Leite¹, Nasrin Asgari¹, Najib Kissani¹, Rogier Hintzen¹, Romain Marignier¹, Sven Jarius¹, John Marcelletti¹, Terry J Smith¹, Michael R Yeaman¹, May H Han¹, Orhan Aktas, Metha Apiwattanakul, Brenda Banwell, Denis Bichuetti, Simon Broadley, Philippe Cabre, Tanuja Chitnis, Jerome De Seze, Kazuo Fujihara, Benjamin Greenberg, Kerstin Hellwig, Raffaele Iorio, Sven Jarius, Eric Klawiter, Ingo Kleiter, Marco Lana-Peixoto, Nakashima, Kevin O'Connor, Jacqueline Palace, Friedman Paul, Naraporn Prayoonwiwat, Klemens Ruprecht, Olaf Stuve, Thomas Tedder, Silvia Tenembaum, Juan P Garrahan, Buenos Aires, Katja van Herle, Danielle van Pelt, Pablo Villoslada, Emmanuelle Waubant, Brian Weinshenker, Dean Wingerchuk, Jens Würfel, Scott Zamvil

Affiliations

Affiliation

¹ Stanford University (E.M., M.H.H.), Stanford, CA; Johns Hopkins University (M.L.), Baltimore, MD; University of Oxford (P.J.W.), UK; Tohoku University (D.K.S.), Sendai, Japan; University of São Paulo (D.K.S.), Brazil; University of Colorado (J.L.B.), Denver; Mt. Sinai University (G.R.J.), New York, NY; Thomas Jefferson University (D.C.H.), Philadelphia, PA; IDIBAPS (A.S.), Barcelona, Spain; Montreal Neurological Institute and Hospital (A.B.-O.), McGill University, Montreal, Quebec, Canada; Research Institute and Hospital of National Cancer Center (H.J.K.), Goyang, Korea; KS Hegde Medical Academy (L.P.), Nitte University, Mangalore, India; Oxford University Hospital (M.I.L.), Oxford, UK; University of Southern Denmark (N.A.), Odense; Vejle Hospital (N.A.), Denmark; University Hospital (N.K.), Marrakech, Morocco; MS Center (R.H.), Erasmus MC University Medical Center, Rotterdam, the Netherlands; Service de Neurologie A (R.M.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France; Molecular Neuroimmunology (S.J.), Department of Neurology, University Hospital Heidelberg, Germany; Tandem Labs (J.M.), San Diego, CA; University of Michigan Medical School (T.J.S.), Ann Arbor, MI; and David Geffen School of Medicine (M.R.Y.), University of California, Los Angeles.

PMID: 26236760
PMCID: PMC4516398
DOI: 10.1212/NXI.0000000000000134

Review

Update on biomarkers in neuromyelitis optica

Esther Melamed et al. Neurol Neuroimmunol Neuroinflamm. 2015.

. 2015 Jul 23;2(4):e134.

doi: 10.1212/NXI.0000000000000134. eCollection 2015 Aug.

Authors

Affiliation

¹ Stanford University (E.M., M.H.H.), Stanford, CA; Johns Hopkins University (M.L.), Baltimore, MD; University of Oxford (P.J.W.), UK; Tohoku University (D.K.S.), Sendai, Japan; University of São Paulo (D.K.S.), Brazil; University of Colorado (J.L.B.), Denver; Mt. Sinai University (G.R.J.), New York, NY; Thomas Jefferson University (D.C.H.), Philadelphia, PA; IDIBAPS (A.S.), Barcelona, Spain; Montreal Neurological Institute and Hospital (A.B.-O.), McGill University, Montreal, Quebec, Canada; Research Institute and Hospital of National Cancer Center (H.J.K.), Goyang, Korea; KS Hegde Medical Academy (L.P.), Nitte University, Mangalore, India; Oxford University Hospital (M.I.L.), Oxford, UK; University of Southern Denmark (N.A.), Odense; Vejle Hospital (N.A.), Denmark; University Hospital (N.K.), Marrakech, Morocco; MS Center (R.H.), Erasmus MC University Medical Center, Rotterdam, the Netherlands; Service de Neurologie A (R.M.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France; Molecular Neuroimmunology (S.J.), Department of Neurology, University Hospital Heidelberg, Germany; Tandem Labs (J.M.), San Diego, CA; University of Michigan Medical School (T.J.S.), Ann Arbor, MI; and David Geffen School of Medicine (M.R.Y.), University of California, Los Angeles.

PMID: 26236760
PMCID: PMC4516398
DOI: 10.1212/NXI.0000000000000134

Abstract

Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO. However, whether AQP4-IgG levels correlate with disease activity, severity, response to therapy, or long-term outcomes is unclear. Moreover, biomarkers for patients with seronegative NMO have yet to be defined and validated. Collaborative international studies hold great promise for establishing and validating biomarkers that are useful in therapeutic trials and clinical management. In this review, we discuss known and potential biomarkers for NMO.

PubMed Disclaimer

Figures

See this image and copyright information in PMC

References

1. Devic E. Myélite subaiguë compliquée de névrite optique. Bull Med 1984;8:1033–1034.
1. Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation 2013;10:8. - PMC - PubMed
1. Beck G. A case of diffuse myelitis associated with optic neuritis. Brain 1927;50:687–703.
1. Popescu BF, Lennon VA, Parisi JE, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 2011;76:1229–1237. - PMC - PubMed
1. Collongues N, Cabre P, Marignier R, et al. A benign form of neuromyelitis optica: does it exist? Arch Neurol 2011;68:918–924. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Update on biomarkers in neuromyelitis optica

Affiliation

Update on biomarkers in neuromyelitis optica

Authors

Affiliation

Abstract

Figures

References

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical